Last reviewed · How we verify

cetuximab, capecitabine

Institute of Oncology Ljubljana · Phase 3 active Small molecule

cetuximab, capecitabine is a EGFR inhibitor, thymidylate synthase inhibitor Small molecule drug developed by Institute of Oncology Ljubljana. It is currently in Phase 3 development for Metastatic colorectal cancer, Head and neck cancer. Also known as: Erbitux, Xeloda.

Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while capecitabine is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor.

Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while capecitabine is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor. Used for Metastatic colorectal cancer, Head and neck cancer.

At a glance

Generic namecetuximab, capecitabine
Also known asErbitux, Xeloda
SponsorInstitute of Oncology Ljubljana
Drug classEGFR inhibitor, thymidylate synthase inhibitor
TargetEGFR, thymidylate synthase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Cetuximab binds to the EGFR on the surface of cancer cells, preventing the receptor from interacting with its ligands and thereby inhibiting cell proliferation. Capecitabine is converted into 5-fluorouracil, which is then incorporated into DNA, causing DNA damage and inhibiting thymidylate synthase, a key enzyme in DNA synthesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about cetuximab, capecitabine

What is cetuximab, capecitabine?

cetuximab, capecitabine is a EGFR inhibitor, thymidylate synthase inhibitor drug developed by Institute of Oncology Ljubljana, indicated for Metastatic colorectal cancer, Head and neck cancer.

How does cetuximab, capecitabine work?

Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while capecitabine is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor.

What is cetuximab, capecitabine used for?

cetuximab, capecitabine is indicated for Metastatic colorectal cancer, Head and neck cancer.

Who makes cetuximab, capecitabine?

cetuximab, capecitabine is developed by Institute of Oncology Ljubljana (see full Institute of Oncology Ljubljana pipeline at /company/institute-of-oncology-ljubljana).

Is cetuximab, capecitabine also known as anything else?

cetuximab, capecitabine is also known as Erbitux, Xeloda.

What drug class is cetuximab, capecitabine in?

cetuximab, capecitabine belongs to the EGFR inhibitor, thymidylate synthase inhibitor class. See all EGFR inhibitor, thymidylate synthase inhibitor drugs at /class/egfr-inhibitor-thymidylate-synthase-inhibitor.

What development phase is cetuximab, capecitabine in?

cetuximab, capecitabine is in Phase 3.

What are the side effects of cetuximab, capecitabine?

Common side effects of cetuximab, capecitabine include Skin rash, Diarrhea, Fatigue, Hand-foot syndrome, Neutropenia.

What does cetuximab, capecitabine target?

cetuximab, capecitabine targets EGFR, thymidylate synthase and is a EGFR inhibitor, thymidylate synthase inhibitor.

Related